Alessandra Mortellaro

Dr. Alessandra Mortellaro


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2002 in Science
Verified
Journal Article
Closed access
PDF file
AAAlessandro Aiuti
Alessandro Aiuti
SSShimon Slavin
Shimon Slavin
MAMemet Aker
Memet Aker
FFFrancesca Ficara
Francesca Ficara
SDSara Deola
Sara Deola
CBClaudio Bordignon
Claudio Bordignon
Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)–deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy because of the small proportion of engrafted genetically corrected HSCs. We describe an improved protocol for gene transfer into HSCs associated with nonmyeloablative conditioning. This protocol was used in two patients for whom enzyme replacement therapy was not available, which allowed the effect of gene therapy alone to be evaluated. Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions (including antigen-specific responses), and lower toxic metabolites. Both patients are currently at home and clinically well, with normal growth and development. These results indicate the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.

1 November 2023 in Nature
Verified
Journal Article
Closed access
PDF file
NCNicoletta Caronni
Nicoletta Caronni
FTFederica La Terza
Federica La Terza
FVFrancesco M. Vittoria
Francesco M. Vittoria
GBGiulia Barbiera
Giulia Barbiera
LMLuca Mezzanzanica
Luca Mezzanzanica
RORenato Ostuni
Renato Ostuni

28 October 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
EVElena Viganò
Elena Viganò
CDCatherine Emma Diamond
Catherine Emma Diamond
RSRoberto Spreafico
Roberto Spreafico
ABAkhila Balachander
Akhila Balachander
Radoslaw SobotaRadoslaw Sobota
Radoslaw Sobota
AMAlessandra Mortellaro
Alessandra Mortellaro
Monocytes promote the early host response to infection releasing key pro-inflammatory cytokines, such as IL-1β. The biologically inactive IL-1β precursor is processed to active form by inflammasomes, multi-protein complexes activating caspase-1. Human monocytes exhibit an unconventional one-step pathway of inflammasome activation in response to lipopolysaccharide (LPS) alone. Although this lineage-restricted mechanism is likely to contribute to the pathology of endotoxin shock, signalling pathways regulating this mechanism are currently unknown. Here we report that caspase-4 and caspase-5 mediate IL-1α and IL-1β release from human monocytes after LPS stimulation. Although caspase-4 remains uncleaved, caspase-5 undergoes rapid processing upon LPS treatment. We also identify an additional caspase-5 cleavage product in LPS-stimulated monocytes, which correlates with IL-1 secretion. This one-step pathway requires Syk activity and Ca2+ flux instigated by CD14/TLR4-mediated LPS internalization. Identification of caspase-4/5 as the key determinants of one-step inflammasome activation in human monocytes provides potential targets for therapeutic intervention in endotoxin shock.

12 February 2016 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
FMF Martín-Sánchez
F Martín-Sánchez
CDC Diamond
C Diamond
MZM Zeitler
M Zeitler
AGA I Gomez
A I Gomez
ABALBERTO BAROJA-MAZO
ALBERTO BAROJA-MAZO
PPPablo Pelegrín
Pablo Pelegrín
Interleukin-1β (IL-1β) is a critical regulator of the inflammatory response. IL-1β is not secreted through the conventional ER–Golgi route of protein secretion, and to date its mechanism of release has been unknown. Crucially, its secretion depends upon the processing of a precursor form following the activation of the multimolecular inflammasome complex. Using a novel and reversible pharmacological inhibitor of the IL-1β release process, in combination with biochemical, biophysical, and real-time single-cell confocal microscopy with macrophage cells expressing Venus-labelled IL-1β, we have discovered that the secretion of IL-1β after inflammasome activation requires membrane permeabilisation, and occurs in parallel with the death of the secreting cell. Thus, in macrophages the release of IL-1β in response to inflammasome activation appears to be a secretory process independent of nonspecific leakage of proteins during cell death. The mechanism of membrane permeabilisation leading to IL-1β release is distinct from the unconventional secretory mechanism employed by its structural homologues fibroblast growth factor 2 (FGF2) or IL-1α, a process that involves the formation of membrane pores but does not result in cell death. These discoveries reveal key processes at the initiation of an inflammatory response and deliver new insights into the mechanisms of protein release.

1 August 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
FEDERICA LAUDISIFEDERICA LAUDISI
FEDERICA LAUDISI
RSRoberto Spreafico
Roberto Spreafico
MEMaximilien Evrard
Maximilien Evrard
THTimothy R Hughes
Timothy R Hughes
BMBarbara Mandriani
Barbara Mandriani
AMAlessandra Mortellaro
Alessandra Mortellaro
The complement system is a potent component of the innate immune response, promoting inflammation and orchestrating defense against pathogens. However, dysregulation of complement is critical to several autoimmune and inflammatory syndromes. Elevated expression of the proinflammatory cytokine IL-1β is often linked to such diseases. In this study, we reveal the mechanistic link between complement and IL-1β secretion using murine dendritic cells. IL-1β secretion occurs following intracellular caspase-1 activation by inflammasomes. We show that complement elicits secretion of both IL-1β and IL-18 in vitro and in vivo via the NLRP3 inflammasome. This effect depends on the inflammasome components NLRP3 and ASC, as well as caspase-1 activity. Interestingly, sublethal complement membrane attack complex formation, but not the anaphylatoxins C3a and C5a, activated the NLRP3 inflammasome in vivo. These findings provide insight into the molecular processes underlying complement-mediated inflammation and highlight the possibility of targeting IL-1β to control complement-induced disease and pathological inflammation.

2 January 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LTLudovic Tailleux
Ludovic Tailleux
SWSimon Waddell
Simon Waddell
Mattia PelizzolaMattia Pelizzola
Mattia Pelizzola
AMAlessandra Mortellaro
Alessandra Mortellaro
MWMichael Withers
Michael Withers
ONOlivier Neyrolles
Olivier Neyrolles
Transcriptional profiling using microarrays provides a unique opportunity to decipher host pathogen cross-talk on the global level. Here, for the first time, we have been able to investigate gene expression changes in both Mycobacterium tuberculosis, a major human pathogen, and its human host cells, macrophages and dendritic cells. In addition to common responses, we could identify eukaryotic and microbial transcriptional signatures that are specific to the cell type involved in the infection process. In particular M. tuberculosis shows a marked stress response when inside dendritic cells, which is in accordance with the low permissivity of these specialized phagocytes to the tubercle bacillus and to other pathogens. In contrast, the mycobacterial transcriptome inside macrophages reflects that of replicating bacteria. On the host cell side, differential responses to infection in macrophages and dendritic cells were identified in genes involved in oxidative stress, intracellular vesicle trafficking and phagosome acidification. This study provides the proof of principle that probing the host and the microbe transcriptomes simultaneously is a valuable means to accessing unique information on host pathogen interactions. Our results also underline the extraordinary plasticity of host cell and pathogen responses to infection, and provide a solid framework to further understand the complex mechanisms involved in immunity to M. tuberculosis and in mycobacterial adaptation to different intracellular environments.